Streetbeat News

Products Services

AREC

American Resources Corporation (AREC), a supplier of rare earth and critical elements, has accepted a term sheet for an investment of up to $50M into its subsidiary, ReElement Technologies, from an investment fund. The investment values ReElement Technologies at a pre-money valuation of $300M.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:34 am

IMVT

Immunovant has been awarded a U.S. patent for IMVT-1402, a significant development that could enhance the company's intellectual property portfolio and potentially impact its market position.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:32 am

BTCUSD

Market analyst Todd Gordon, founder of Inside Edge Capital, discussed Bitcoin's performance on CNBC's 'Last Call,' highlighting its resilience compared to the sharp decline in semiconductor stocks. Despite Bitcoin's recent surge to over $72,000, Gordon does not believe it is overvalued and sees potential for further growth, especially in relation to tech and semiconductor stocks. He mentioned owning Bitcoin and Bitcoin ETFs, considering adding Bitcoin to his wealth management portfolios.

Portfolio Pulse from Benzinga Neuro

March 12, 2024 | 11:29 am

AUTL

Autolus Therapeutics' Nucleus manufacturing facility in Stevenage has received Manufacturer's Importation Authorization from the MHRA following a recent GMP inspection. This authorization, effective March 18, enables the facility to manufacture for global commercial and clinical product supply.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:13 am

OSW

OneSpaWorld (OSW) has been named the exclusive spa provider for Royal Caribbean International through a new multi-year partnership. This collaboration is expected to enhance the guest experience on Royal Caribbean cruises by offering premium spa services.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:11 am

ENVB

Enveric Biosciences announced that the US Patent and Trademark Office issued a patent for 'Multi-substituent Psilocybin Derivatives' on March 5 and is expected to issue another patent for 'Nitrilated Psilocybin Derivatives' on March 19. These patents represent significant advancements in the company's psychedelic compound development efforts.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:10 am

BCDA

BioCardia has received CMS approval for coverage of its CardiAMP Cell Therapy Phase III study in heart failure, potentially accelerating patient enrollment and advancing the therapy's development.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:04 am

TSLA

Canaccord Genuity analyst George Gianarikas views Tesla Inc (TSLA) as a solid buy, setting a price target of over $230. He attributes the current stock slump to poor earnings revisions but is optimistic about Tesla's growth in vehicle prices, next-gen vehicles, FSD adoption, and energy storage. Despite aggressive price cuts to boost sales, Tesla's strategy pressures rivals and maintains competitiveness, especially in the US, Europe, and China.

Portfolio Pulse from Anan Ashraf

March 12, 2024 | 10:45 am

KALV

KalVista Pharmaceuticals has received the Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency for Sebetralstat, a treatment for Hereditary Angioedema.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:38 am

MNOV

MediciNova announced new data and results for MN-166 (Ibudilast) in treating chlorine gas-induced acute lung injury at the Society of Toxicology's annual meeting. This development could signal progress in their research and potential for future applications.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 10:36 am